. Author manuscript; available in PMC: 2017 Jun 1.

Published in final edited form as: J Bone Miner Res. 2016 Feb 15;31(6):1137–1145. doi: 10.1002/jbmr.2779

Table 3.

The Association (With 95% Confidence Intervals) Between Antihypertensive Medication Class and PTH Level

Model	Thiazide		Loop Diuretic		CCB
Model	β (95% CI)	p value	β (95% CI)	p value	β (95% CI)	p value
Univariate	−2.3 (−4.3, −0.4)	0.02	+15.2 (11.0, 19.4)	<0.0001	+5.1 (3.3, 7.0)	<0.0001
Multivariate A	−4.2 (−6.1, −2.3)	<0.0001	+12.2 (8.1, 16.3)	<0.0001	+4.3 (2.6, 6.1)	<0.0001
Multivariate B	−3.3 (−5.2, −1.4)	0.0007	+11.4 (7.3, 15.4)	<0.0001	+3.7 (1.9, 5.5)	<0.0001
Multivariate C	−3.2 (−5.1, −1.4)	0.0007	+12.0 (8.1, 16.0)	<0.0001	+3.7 (1.9, 5.4)	<0.0001

PTH =parathyroid hormone; CCB =calcium-channel blocker.

Units for β are pg/mL of PTH per use of antihypertensive drug.

Multivariate A: adjusted for age, ethnicity, sex, body mass index (BMI), vitamin D25OH, estimated glomerular filtration rate (eGFR), diabetes status, education level, cigarette smoking, and physical activity.

Multivariate B: adjusted for age, ethnicity, sex, BMI, vitamin D25OH, eGFR, systolic blood pressure, diabetes status, education level, cigarette smoking, physical activity, and other antihypertensive medication use (HCTZ: adjusted for use of loop diuretics, calcium-channel blockers, RAAS-inhibitor, beta-blocker, and alpha-blocker use; loop diuretics: adjusted for use of thiazide, calcium-channel blockers, RAAS-inhibitor, beta-blocker, and alpha-blocker use; CCB: adjusted for use of thiazide, loop diuretics, RAAS-inhibitor, beta-blocker, and alpha-blocker use).

Multivariate C: adjusted for age, ethnicity, sex, BMI, vitamin D25OH, eGFR, systolic blood pressure, diabetes status, education level, cigarette smoking, physical activity, other antihypertensive medication class use, serum calcium, serum phosphate, urinary calcium/cr, urinary phosphate/cr, and FGF-23.